The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis

A report from the glucosamine/chondroitin arthritis intervention trial

Allen D. Sawitzke, Helen Shi, Martha F. Finco, Dorothy D. Dunlop, Clifton O. Bingham, Crystal L. Harris, Nora G. Singer, John D. Bradley, David Silver, Christopher G. Jackson, Nancy E. Lane, Chester V. Oddis, Fred Wolfe, Jeffrey R Lisse, Daniel E. Furst, Domenic J. Reda, Roland W. Moskowitz, H. James Williams, Daniel O. Clegg

Research output: Contribution to journalArticle

175 Citations (Scopus)

Abstract

Objective. Osteoarthritis (OA) of the knee causes significant morbidity and current medical treatment is limited to symptom relief, while therapies able to slow structural damage remain elusive. This study was undertaken to evaluate the effect of glucosamine and chondroitin sulfate (CS), alone or in combination, as well as celecoxib and placebo on progressive loss of joint space width (JSW) in patients with knee OA. Methods. A 24-month, double-blind, placebo-controlled study, conducted at 9 sites in the United States as part of the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), enrolled 572 patients with knee OA who satisfied radiographic criteria (Kellgren/ Lawrence [K/L] grade 2 or grade 3 changes and JSW of at least 2 mm at baseline). Patients with primarily lateral compartment narrowing at any time point were excluded. Patients who had been randomized to 1 of the 5 groups in the GAIT continued to receive glucosamine 500 mg 3 times daily, CS 400 mg 3 times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. The minimum medial tibiofemoral JSW was measured at baseline, 12 months, and 24 months. The primary outcome measure was the mean change in JSW from baseline. Results. The mean JSW loss at 2 years in knees with OA in the placebo group, adjusted for design and clinical factors, was 0.166 mm. No statistically significant difference in mean JSW loss was observed in any treatment group compared with the placebo group. Treatment effects on K/L grade 2 knees, but not on K/L grade 3 knees, showed a trend toward improvement relative to the placebo group. The power of the study was diminished by the limited sample size, variance of JSW measurement, and a smaller than expected loss in JSW. Conclusion. At 2 years, no treatment achieved a predefined threshold of clinically important difference in JSW loss as compared with placebo. However, knees with K/L grade 2 radiographic OA appeared to have the greatest potential for modification by these treatments.

Original languageEnglish (US)
Pages (from-to)3183-3191
Number of pages9
JournalArthritis and Rheumatism
Volume58
Issue number10
DOIs
StatePublished - Oct 2008

Fingerprint

Chondroitin
Chondroitin Sulfates
Knee Osteoarthritis
Glucosamine
Arthritis
Joints
Placebos
Celecoxib
Knee
Therapeutics
Osteoarthritis
Sample Size
Outcome Assessment (Health Care)
Morbidity

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Rheumatology
  • Pharmacology (medical)

Cite this

The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis : A report from the glucosamine/chondroitin arthritis intervention trial. / Sawitzke, Allen D.; Shi, Helen; Finco, Martha F.; Dunlop, Dorothy D.; Bingham, Clifton O.; Harris, Crystal L.; Singer, Nora G.; Bradley, John D.; Silver, David; Jackson, Christopher G.; Lane, Nancy E.; Oddis, Chester V.; Wolfe, Fred; Lisse, Jeffrey R; Furst, Daniel E.; Reda, Domenic J.; Moskowitz, Roland W.; Williams, H. James; Clegg, Daniel O.

In: Arthritis and Rheumatism, Vol. 58, No. 10, 10.2008, p. 3183-3191.

Research output: Contribution to journalArticle

Sawitzke, AD, Shi, H, Finco, MF, Dunlop, DD, Bingham, CO, Harris, CL, Singer, NG, Bradley, JD, Silver, D, Jackson, CG, Lane, NE, Oddis, CV, Wolfe, F, Lisse, JR, Furst, DE, Reda, DJ, Moskowitz, RW, Williams, HJ & Clegg, DO 2008, 'The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial', Arthritis and Rheumatism, vol. 58, no. 10, pp. 3183-3191. https://doi.org/10.1002/art.23973
Sawitzke, Allen D. ; Shi, Helen ; Finco, Martha F. ; Dunlop, Dorothy D. ; Bingham, Clifton O. ; Harris, Crystal L. ; Singer, Nora G. ; Bradley, John D. ; Silver, David ; Jackson, Christopher G. ; Lane, Nancy E. ; Oddis, Chester V. ; Wolfe, Fred ; Lisse, Jeffrey R ; Furst, Daniel E. ; Reda, Domenic J. ; Moskowitz, Roland W. ; Williams, H. James ; Clegg, Daniel O. / The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis : A report from the glucosamine/chondroitin arthritis intervention trial. In: Arthritis and Rheumatism. 2008 ; Vol. 58, No. 10. pp. 3183-3191.
@article{02306ea6c2784c578b2cf7e2171a404b,
title = "The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: A report from the glucosamine/chondroitin arthritis intervention trial",
abstract = "Objective. Osteoarthritis (OA) of the knee causes significant morbidity and current medical treatment is limited to symptom relief, while therapies able to slow structural damage remain elusive. This study was undertaken to evaluate the effect of glucosamine and chondroitin sulfate (CS), alone or in combination, as well as celecoxib and placebo on progressive loss of joint space width (JSW) in patients with knee OA. Methods. A 24-month, double-blind, placebo-controlled study, conducted at 9 sites in the United States as part of the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), enrolled 572 patients with knee OA who satisfied radiographic criteria (Kellgren/ Lawrence [K/L] grade 2 or grade 3 changes and JSW of at least 2 mm at baseline). Patients with primarily lateral compartment narrowing at any time point were excluded. Patients who had been randomized to 1 of the 5 groups in the GAIT continued to receive glucosamine 500 mg 3 times daily, CS 400 mg 3 times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. The minimum medial tibiofemoral JSW was measured at baseline, 12 months, and 24 months. The primary outcome measure was the mean change in JSW from baseline. Results. The mean JSW loss at 2 years in knees with OA in the placebo group, adjusted for design and clinical factors, was 0.166 mm. No statistically significant difference in mean JSW loss was observed in any treatment group compared with the placebo group. Treatment effects on K/L grade 2 knees, but not on K/L grade 3 knees, showed a trend toward improvement relative to the placebo group. The power of the study was diminished by the limited sample size, variance of JSW measurement, and a smaller than expected loss in JSW. Conclusion. At 2 years, no treatment achieved a predefined threshold of clinically important difference in JSW loss as compared with placebo. However, knees with K/L grade 2 radiographic OA appeared to have the greatest potential for modification by these treatments.",
author = "Sawitzke, {Allen D.} and Helen Shi and Finco, {Martha F.} and Dunlop, {Dorothy D.} and Bingham, {Clifton O.} and Harris, {Crystal L.} and Singer, {Nora G.} and Bradley, {John D.} and David Silver and Jackson, {Christopher G.} and Lane, {Nancy E.} and Oddis, {Chester V.} and Fred Wolfe and Lisse, {Jeffrey R} and Furst, {Daniel E.} and Reda, {Domenic J.} and Moskowitz, {Roland W.} and Williams, {H. James} and Clegg, {Daniel O.}",
year = "2008",
month = "10",
doi = "10.1002/art.23973",
language = "English (US)",
volume = "58",
pages = "3183--3191",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "10",

}

TY - JOUR

T1 - The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis

T2 - A report from the glucosamine/chondroitin arthritis intervention trial

AU - Sawitzke, Allen D.

AU - Shi, Helen

AU - Finco, Martha F.

AU - Dunlop, Dorothy D.

AU - Bingham, Clifton O.

AU - Harris, Crystal L.

AU - Singer, Nora G.

AU - Bradley, John D.

AU - Silver, David

AU - Jackson, Christopher G.

AU - Lane, Nancy E.

AU - Oddis, Chester V.

AU - Wolfe, Fred

AU - Lisse, Jeffrey R

AU - Furst, Daniel E.

AU - Reda, Domenic J.

AU - Moskowitz, Roland W.

AU - Williams, H. James

AU - Clegg, Daniel O.

PY - 2008/10

Y1 - 2008/10

N2 - Objective. Osteoarthritis (OA) of the knee causes significant morbidity and current medical treatment is limited to symptom relief, while therapies able to slow structural damage remain elusive. This study was undertaken to evaluate the effect of glucosamine and chondroitin sulfate (CS), alone or in combination, as well as celecoxib and placebo on progressive loss of joint space width (JSW) in patients with knee OA. Methods. A 24-month, double-blind, placebo-controlled study, conducted at 9 sites in the United States as part of the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), enrolled 572 patients with knee OA who satisfied radiographic criteria (Kellgren/ Lawrence [K/L] grade 2 or grade 3 changes and JSW of at least 2 mm at baseline). Patients with primarily lateral compartment narrowing at any time point were excluded. Patients who had been randomized to 1 of the 5 groups in the GAIT continued to receive glucosamine 500 mg 3 times daily, CS 400 mg 3 times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. The minimum medial tibiofemoral JSW was measured at baseline, 12 months, and 24 months. The primary outcome measure was the mean change in JSW from baseline. Results. The mean JSW loss at 2 years in knees with OA in the placebo group, adjusted for design and clinical factors, was 0.166 mm. No statistically significant difference in mean JSW loss was observed in any treatment group compared with the placebo group. Treatment effects on K/L grade 2 knees, but not on K/L grade 3 knees, showed a trend toward improvement relative to the placebo group. The power of the study was diminished by the limited sample size, variance of JSW measurement, and a smaller than expected loss in JSW. Conclusion. At 2 years, no treatment achieved a predefined threshold of clinically important difference in JSW loss as compared with placebo. However, knees with K/L grade 2 radiographic OA appeared to have the greatest potential for modification by these treatments.

AB - Objective. Osteoarthritis (OA) of the knee causes significant morbidity and current medical treatment is limited to symptom relief, while therapies able to slow structural damage remain elusive. This study was undertaken to evaluate the effect of glucosamine and chondroitin sulfate (CS), alone or in combination, as well as celecoxib and placebo on progressive loss of joint space width (JSW) in patients with knee OA. Methods. A 24-month, double-blind, placebo-controlled study, conducted at 9 sites in the United States as part of the Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT), enrolled 572 patients with knee OA who satisfied radiographic criteria (Kellgren/ Lawrence [K/L] grade 2 or grade 3 changes and JSW of at least 2 mm at baseline). Patients with primarily lateral compartment narrowing at any time point were excluded. Patients who had been randomized to 1 of the 5 groups in the GAIT continued to receive glucosamine 500 mg 3 times daily, CS 400 mg 3 times daily, the combination of glucosamine and CS, celecoxib 200 mg daily, or placebo over 24 months. The minimum medial tibiofemoral JSW was measured at baseline, 12 months, and 24 months. The primary outcome measure was the mean change in JSW from baseline. Results. The mean JSW loss at 2 years in knees with OA in the placebo group, adjusted for design and clinical factors, was 0.166 mm. No statistically significant difference in mean JSW loss was observed in any treatment group compared with the placebo group. Treatment effects on K/L grade 2 knees, but not on K/L grade 3 knees, showed a trend toward improvement relative to the placebo group. The power of the study was diminished by the limited sample size, variance of JSW measurement, and a smaller than expected loss in JSW. Conclusion. At 2 years, no treatment achieved a predefined threshold of clinically important difference in JSW loss as compared with placebo. However, knees with K/L grade 2 radiographic OA appeared to have the greatest potential for modification by these treatments.

UR - http://www.scopus.com/inward/record.url?scp=54949121728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54949121728&partnerID=8YFLogxK

U2 - 10.1002/art.23973

DO - 10.1002/art.23973

M3 - Article

VL - 58

SP - 3183

EP - 3191

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 10

ER -